CLYM Climb Bio Inc

Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually February 11-12, 2025.

Oppenheimer 35th Annual Healthcare Life Sciences Conference Format: Presentation and one-on-one investor meetingsDate: February 12, 2025Time: 9:20 a.m. ETWebcast: Click here

About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.  

InvestorsChris Brinzey ICR Healthcarechris.brinzey@icrhealthcare.com339-970-2843

MediaJon YuICR Healthcarejon.yu@icrhealthcare.com475-395-5375